ADVERTISEMENT

Highlights from the San Antonio Breast Cancer Symposium 2009: An Update

A recap of the 2008 San Antonio Breast Cancer Symposium. 

BY STAFF REPORTS
PUBLISHED WEDNESDAY, DECEMBER 8, 2010
Many women develop breast tumors that are sensitive to estrogen—a female hormone that can feed a tumor’s growth and development. So for the past 15 years, researchers have experimented with hormonal drugs to figure out which drugs work best, how they should be sequenced (if giving more than one hormonal agent), and how long they should be taken.

In February 2008, Avastin (bevacizumab) received approval for metastatic breast cancer, despite the fact that an advisory panel for the FDA said the drug did not offer enough benefit (specifically in survival) to justify its use. Hoping to more clearly define the potential and the limits of the drug, researchers have continued testing Avastin in breast cancer, including as second-line therapy.

New data from the RIBBON-2 trial involved 684 women with HER2-negative metastatic breast cancer who had already received one course of chemotherapy. The women received another session of chemotherapy with or without Avastin.

The results: Adding Avastin to chemotherapy as a second-line treatment increased progression-free survival—the length of time the disease did not worsen—by approximately two months (from 5.1 months to 7.2 months). Furthermore, the RIBBON-2 study has not found an improvement in overall survival with the addition of Avastin, but 43 percent of women in the study were still alive.

In July, an FDA advisory panel met and recommended revoking the approval due to the disappointing results from RIBBON-2 and other more recent Avastin trials. A previous study had shown progression-free survival increase of about five months—data on which the FDA had originally based its accelerated approval decision. The FDA is expected to make a decision on Avastin by Dec. 17.

Read the full article here.

Scientists at the 2009 San Antonio Breast Cancer Symposium reported on women who initially started on the aromatase inhibitor Aromasin (exemestane) did no better than the women who switched to Aromasin later from tamoxifen. Regarding the likelihood of cancer recurring or a difference in survival, researcher Daniel Rea, MD, of the University of Birmingham said, "There is no difference whatsoever."

Another study examined whether being premenopausal at diagnosis made a difference in outcomes. All women were menopausal during the study, either naturally, because of surgical removal of the ovaries or because of chemotherapy treatment. Premenopausal women who took tamoxifen for five years, followed by another aromatase inhibitor called Femara (letrozole), were less likely to have a recurrence than women who took only tamoxifen for the initial five years. 

Read the full article here.

Taking Herceptin (trastuzumab) with, as opposed to after, chemotherapy helped more women live longer without a recurrence, new research found.

Investigators randomly assigned roughly 3,000 patients with stage 1 to stage 3 HER2-positive breast cancer who had already undergone surgery to receive either chemotherapy alone (Adriamycin [doxorubicin] and cyclophosphamide followed by Taxol [paclitaxel]), chemotherapy followed by Herceptin or chemotherapy given with Herceptin (paired with Taxol).

ADVERTISEMENT
Related Articles
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Overcoming the Mental Battle of  Metastatic Cancer
The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$